Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Evoke Pharma Inc | evok-ex322_10.htm |
| EX-32.1 - EX-32.1 - Evoke Pharma Inc | evok-ex321_12.htm |
| EX-31.2 - EX-31.2 - Evoke Pharma Inc | evok-ex312_11.htm |
| EX-31.1 - EX-31.1 - Evoke Pharma Inc | evok-ex311_8.htm |
| EX-10.26 - EX-10.26 - Evoke Pharma Inc | evok-ex1026_665.htm |
| EX-10.25 - EX-10.25 - Evoke Pharma Inc | evok-ex1025_826.htm |
| EX-10.24 - EX-10.24 - Evoke Pharma Inc | evok-ex1024_664.htm |
| 10-K - EVOK-10K-20161231 - Evoke Pharma Inc | evok-10k_20161231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Evoke Pharma, Inc.
Solana Beach, California
We hereby consent to the incorporation by reference in Registration Statements on Form S-3 (No. 333-200176) and Form S-8 (No. 133-191518) of Evoke Pharma, Inc. of our report dated March 15, 2017, relating to the financial statements, which appears in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
San Diego, California
March 15, 2017